Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-12-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (419 characters) about a wholly-owned subsidiary receiving a high-tech enterprise certification. It is a regulatory announcement about a certification or recognition, not a financial report or detailed management information. It does not contain financial data, earnings, or governance changes. It is not a report publication announcement since it does not mention any report release. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2021-12-03 Chinese
关于公司董事、高级管理人员股份减持计划期限届满的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the expiration of a share reduction plan by a company's director and senior management. It details the shareholding before and after the plan, confirms compliance with relevant laws and regulations, and states that no shares were actually reduced during the plan period. The content focuses on insider share transactions and compliance disclosures related to those transactions. There is no financial report, earnings data, or management discussion. The document fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives.
2021-11-26 Chinese
关于控股子公司获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology (Group) Co., Ltd. regarding its controlling subsidiary obtaining approval for a drug clinical trial from the National Medical Products Administration. It details the approval notice, drug development information, and risk warnings. The document is an announcement of a regulatory event related to drug development, not a financial report, management change, or shareholder meeting material. It is a regulatory announcement about a significant corporate event but does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length (898 characters), it is best classified under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-11-25 Chinese
关于部分募集资金专户注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the cancellation of a special account for raised funds related to a non-public stock issuance. It details the use and closure of a fundraising account, references regulatory approvals, and provides specifics about the fundraising and account status. The document is short (1617 characters) and serves as a formal notification rather than a detailed financial report or audit. It does not contain financial statements or detailed financial analysis but rather informs about the status of fundraising accounts and compliance with regulatory requirements. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2021-11-23 Chinese
关于公司董事、监事、高级管理人员股份减持计划期限届满的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the expiration of a share reduction plan by company directors and senior management. It details the shareholding changes and compliance with relevant regulations. It is not a financial report, earnings release, or management discussion. It specifically reports on transactions by directors and senior management in their personal capacity regarding company shares. This fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on this topic, confirming it is not a broader report or announcement of a report publication.
2021-11-19 Chinese
关于对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company's external investment in a new investment fund, including the fund's structure, partners, investment strategy, management, and potential risks. It is not a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly results. It is a formal announcement of a capital investment activity by the company. The document length is over 7,000 characters and contains substantive details about the investment fund and the company's involvement. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. There is no indication that this is a report publication announcement or a regulatory filing fallback. Therefore, the correct classification is CAP with high confidence.
2021-11-18 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.